

Printed as of 12/7/2025

Disclosures

Personal Commercial (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	Other
Takeda Pharmaceuticals North America, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Clinian Litratus Francisco (42)			
Advance Medical	Other - Case reviewer	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Self			
Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)

Clinical Trial Enroller (12)

Trial Name	Trial Sponsor	Trial Funding Source
AIRES HM3	Abbott Laboratories	
ATRIUM	Bristol Myers Squibb	
CK-3773274 for oHCM	Cytokinetics, Inc.	
PROACTIVE-HF	Endotronix, Inc.	
Surgical Interventions for Moderate Ischemic Mitral Regurgitation	Mount Sinai Medical Center	NIH-NHLBI
Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic	Mount Sinai Medical Center	NIH-NHLBI
VALOR-HCM	MyoKardia	
MAVA-LTE	MyoKardia	
Prognostic Value of Coronary Flow Reserve in Patients with Ischemic Heart Disease	National Institutes of Health	
REBIRTH	NHLBI	
LOFT-HF	Ohio State University	
GUIDE-HF	St Jude Medical	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 12/11/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Embargo | Signed on 12/11/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/6/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.